ESSA Pharma, Inc.
(TSX Venture Exchange : EPIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-6.21%127.720.7%$1062.40m
MRKMerck & Co., Inc.
1.07%84.700.7%$636.75m
PFEPfizer Inc.
0.00%36.460.9%$629.75m
ABBVAbbVie, Inc.
1.77%76.472.3%$578.88m
BMYBristol-Myers Squibb Company
1.15%53.021.4%$522.05m
LLYEli Lilly and Company
0.16%108.631.0%$298.35m
NVSNovartis AG Sponsored ADR
-0.39%86.890.2%$144.58m
AZNAstraZeneca PLC Sponsored ADR
-0.59%43.871.2%$133.90m
GSKGlaxoSmithKline plc Sponsored ADR
0.12%42.520.2%$97.15m
SNYSanofi Sponsored ADR
-0.71%46.170.2%$75.70m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.29%52.530.1%$68.10m
LCILannett Company, Inc.
-1.84%11.7335.6%$15.44m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.87%1.691.6%$0.44m
EPIXESSA Pharma Inc
8.79%3.900.1%$0.11m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.